lonafarnib · Sentynl Theraps Inc · NDA 213969
Zokinvy
Earliest generic entry, as listed · earliest of 2 marketed strengths
26 Jul 2029
Blocked by patent: US 7838531. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7838531 | use U-3070 | 26 Jul 2029 |
Exclusivities · 1 unexpired
| ODE-324 | orphan drug (7 years) | 20 Nov 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213969 · 001 · RLD | capsule, oral | 50MG | 26 Jul 2029 |
| 213969 · 002 · RLD | capsule, oral | 75MG | 26 Jul 2029 |